ADAPTIMMUNE THERAPEUTICS-ADR (ADAP)

US00653A1079 - ADR

1.27  +0.02 (+2.01%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (7/16/2024, 3:30:00 PM)

1.27

+0.02 (+2.01%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month80.76%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap324.56M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADAP Daily chart

Company Profile

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Abingdon, Oxfordshire and currently employs 534 full-time employees. The company went IPO on 2015-05-06. The firm is focused on providing cell therapies to people with cancer. The company develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Company Info

ADAPTIMMUNE THERAPEUTICS-ADR

60 Jubilee Avenue

Abingdon OXFORDSHIRE OX14 4RX

P: 441235430000

CEO: Adrian Rawcliffe

Employees: 534

Website: https://www.adaptimmune.com/

ADAP News

News Image13 days ago - InvestorPlace3 Biotech Moonshots With Imminent Catalyst Potential

Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts.

News Imagea month ago - NewsfileAdaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response...

News Image2 months ago - AB NewswireIntelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
News Image2 months ago - InvestorPlaceToday‚Äôs Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers on Friday morning!

News Image2 months ago - NewsfileAdaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...

News Image2 months ago - InvestorPlaceADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024

ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

ADAP Twits

Here you can normally see the latest stock twits on ADAP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example